lcalvobartolome/proxann_data huggingface dataset:
Topic: Health — R&D
Subject: Health
Date: 2014-11-18 00:00:00

Adding Ebola to the FDA Priority Review Voucher Program Act - Amends the Federal Food, Drug, and Cosmetic Act to add filoviruses, a family of viruses that includes the Ebola virus, to the list of tropical diseases under the priority review voucher program, which awards vouchers to sponsors of human drug applications that are approved to prevent or treat tropical diseases. (A voucher entitles the holder to have a future human drug application acted upon by the Food and Drug Administration (FDA) within six months.)

Changes the process by which infectious diseases that do not significantly impact developed nations and disproportionately affect poor and marginalized populations can be designated as tropical diseases from rulemaking to order of the Secretary of Health and Human Services (HHS).

Allows priority review vouchers to be transferred between sponsors of human drug applications any number of times.

Reduces from 365 days to 90 days the advance notice required before submitting a human drug application subject to a priority review voucher.
Topic: Health — R&D
Subject: Health
Date: 2014-12-03 00:00:00

Health Prizes Rewarding Innovation, Savings, and Effectiveness Act of 2014 - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH) to design prize competitions open to competitors worldwide to realize innovations that improve health outcomes thereby reducing federal expenditures on health programs.

Requires the NIH to identify as the subject of the competitions diseases or health conditions for which the federal government spends at least $5 billion per year on prevention and treatment, and the research investment is disproportionately small in comparison to other diseases with similar or greater federal expenditures on treatment and prevention.

Directs the NIH to award contracts to perform a simulation of the designed prize competitions to assess the effectiveness of the design.

Requires the NIH to contract with private entities to implement the competitions.

Allows the Secretary of Health and Human Services (HHS) and the Food and Drug Administration (FDA) to provide competitors with guidance and access to testing facilities.

Prohibits the federal government from gaining an interest in intellectual property development by a participant without the participant's written consent.

Amends the Internal Revenue Code to exclude prizes from gross income.
Topic: Health — R&D
Subject: Science, technology, communications
Date: 2014-12-09 00:00:00

Funding Scientists at the Peak Age of Discovery Act of 2014 - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH) to ensure that the median age of first-time researchers receiving R series (research) grants is under 40 years of age by January 1, 2019, under 39 years of age by January 1, 2022, and under 38 years of age by January 1, 2025. Excludes grants for small business innovation research, small business technology transfer, or clinical trial planning.
Topic: Health — R&D
Subject: Science, technology, communications
Date: 2014-12-09 00:00:00

YES to Cures Act of 2014 - Amends the Public Health Service Act to require the Secretary of Health and Human Services (HHS) to allocate for research by emerging scientists funds that otherwise would be used to evaluate the implementation and effectiveness of National Institutes of Health (NIH) programs.

Requires NIH to explain why there has been an increase in the average age of grant recipients over the past 30 years and describe the steps taken to address this trend.
Topic: Health — R&D
Subject: Environmental protection
Date: 2013-01-22 00:00:00

Strengthening Protections for Children and Communities From Disease Clusters Act - Requires the Administrator of the Environmental Protection Agency (EPA) to: (1) develop, publish, and update guidelines on an approach to investigate suspected or potential disease clusters, environmental pollutants or toxic substances associated with such clusters, or potential causes of such clusters; (2) establish and operate Regional Disease Cluster Information and Response Centers and Regional Disease Cluster Information and Response Teams; (3) ensure that the Office of Children's Health Protection has a prominent role in developing and updating such guidelines and in establishing and operating such Centers and Teams; (4) establish Community Disease Cluster Advisory Committees to provide oversight, guidance, and advice relating to such investigations; (5) provide support to individuals on such Teams and Committees through grants and cooperative agreements with institutions of higher education; (6) compile and update a publicly available, online database that provides information relating to disease clusters; and (7) use available authorities and programs to compile, research, and analyze information generated by actions authorized under this Act.

Authorizes any person to submit a petition to the EPA Administrator, the Administrator of the Agency for Toxic Substances and Disease Registry, and the Director of the National Institute of Environmental Health Sciences that requests that a Response Team conduct an investigation or take action to address the potential causes of disease clusters.

Authorizes the Administrator to make grants to any group of individuals that may be affected by such clusters.
Topic: Health — R&D
Subject: Taxation
Date: 2013-01-24 00:00:00

Ethical Stem Cell Research Tax Credit Act of 2013 - Amends the Internal Revenue Code to allow a tax credit for 30% of qualified stem cell research expenses paid or incurred in a taxable year. Defines "qualified stem cell research expenses" as expenses for carrying out basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of or treatments for diseases and other adverse health conditions. Prohibits a tax credit for any research expenses that may involve: (1) the creation of a human embryo for research purposes; (2) the destruction of or discarding of, or risk of injury to, a human embryo; or (3) the use of any stem cell for prohibited purposes.
Topic: Health — R&D
Subject: Foreign trade and international finance
Date: 2013-02-04 00:00:00

Citrus Disease Research and Development Trust Fund Act of 2013 - Amends the Trade Act of 1974 to establish the Citrus Disease Research and Development Trust Fund, consisting of revenues from duties paid on imported citrus or citrus products, to support scientific research, technical assistance, and development activities to combat both domestic and invasive citrus diseases and pests harming the United States.

 Establishes the Citrus Disease Research and Development Trust Fund Advisory Board.

Makes Fund amounts available to the Secretary of Agriculture to develop a coordinated program of research and product development relating to: (1) scientific research of both domestic and invasive diseases and pests afflicting the citrus industry; and (2) support for the dissemination and commercialization of relevant information, techniques, and technologies discovered through Fund research or other research projects intended to solve problems caused by citrus production diseases and invasive pests.

Requires the President to notify certain congressional committees before entering into a trade agreement that could result in a decrease in the amount of: (1) duties paid on imported citrus or citrus products, and (2) funds transferred into the Fund.

Prescribes a formula for required estimated tax payments otherwise due in each of the quarters of 2018 from corporations with assets of at least $1 billion.

Amends the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA) to extend certain customs users fees for the processing of merchandise entered into the United States between October 23, 2021, and November 6, 2021, and other specified customs users fees for merchandise entered between October 30, 2021, and November 13, 2021.
Topic: Health — R&D
Subject: Health
Date: 2013-02-28 00:00:00

National Pediatric Research Network Act of 2013 - Amends the Public Health Service Act to authorize the Director of the National Institutes of Health (NIH), in carrying out the Pediatric Research Initiative, to act through the Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development to provide for the establishment of a National Pediatric Research Network.

Authorizes the Director of the Institute to award funding to public or private nonprofit entities for: (1) planning, establishing, or strengthening pediatric research consortia; and (2) providing basic operating support for such consortia, including to meet unmet needs for pediatric research through basic, clinical and behavioral translational research and the training of researchers in pediatric research techniques. Authorizes the Director of NIH to make awards for not more than 20 pediatric research consortia, which must be formed from a collaboration of cooperating institutions, coordinated by a lead institution, agree to disseminate scientific findings, and meet requirements prescribed by the Director of NIH. Allows such support to be for a period of five years, with additional extensions at the discretion of the Director of NIH.

Requires the Director of NIH to provide for the coordination of activities among the consortia and to require the periodic preparation and submission of reports on their activities. Requires each pediatric research consortium receiving an award to assist the Centers for Disease Control and Prevention (CDC) in the establishment or expansion of patient registries and other surveillance systems as appropriate and upon request by the CDC.

Requires the Director of NIH to ensure that an appropriate number of such awards are awarded to consortia that agree to: (1) focus primarily on pediatric rare diseases or conditions; and (2) conduct or coordinate multi-site clinical trials of therapies for, or approaches to, the prevention, diagnosis, or treatment of pediatric rare diseases or conditions.

Requires the Director of NIH to establish a data coordinating center to: (1) distribute such findings; (2) provide assistance in the design and conduct of collaborative research projects and the management, analysis, and storage of data associated with such projects; and (3) organize and conduct multi-site monitoring activities.

Requires the Director of NIH to: (1) require the data coordinating center to provide regular reports to the Director of NIH and the Commissioner of Food and Drugs (FDA) on research conducted by consortia, including information on enrollment in clinical trials and the allocation of resources with respect to such research; and (2) incorporate such information into NIH's biennial reports.
Topic: Health — R&D
Subject: Health
Date: 2013-03-20 00:00:00

Prize Fund for HIV/AIDS Act - Denies any person the exclusive right to manufacture, distribute, sell, or use in interstate commerce a qualifying treatment for HIV/AIDS, or to a manufacturing process for such a treatment, including the exclusive right to rely on health registration data or the 30-month stay-of-effectiveness period for Orange Book patents. Prescribes remuneration, in the form of prize payments from a Prize Fund for HIV/AIDS, in lieu of such market exclusivity.

Exempts from this elimination of exclusive rights any dual use product that is a qualifying treatment for HIV/AIDS which also has a significant use for other diseases, but only with respect to its use for other diseases. Applies the elimination of exclusive rights with respect to a qualifying HIV/AIDS treatment even in a dual use product.

Establishes the Prize Fund for HIV/AIDS. Requires the Secretary of Health and Human Services (HHS) to designate a Prize Fund Director to administer the Fund.

Directs the Prize Fund Director to award prize payments for medical innovation relating to a qualifying treatment for HIV/AIDS, or a new manufacturing process for such a treatment, to: (1) the first person to receive market clearance with respect to the drug or biological product; (2) the holder of the patent with respect to a manufacturing process; or (3) persons or communities that as an open source contribution openly shared knowledge, data, materials, and technology on a royalty-free and nondiscriminatory basis.

Allows the Prize Fund Director to authorize multiple nonprofit intermediaries to manage Fund payments to reward projects for: (1) interim research and development of new qualifying treatments for HIV/AIDS, or (2) open source dividend prizes.

Establishes an annual fee for health insurers to fund this Act.

Establishes the Donor Innovation Prize Fund to enable the Secretary to reward owners and developers of products that permit open competition for low-cost generic drugs for the treatment of HIV/AIDS in developing countries.
Topic: Health — R&D
Subject: Health
Date: 2013-03-21 00:00:00

Collaborative Academic Research Efforts for Tourette Syndrome Act of 2013 - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH programs and activities regarding Tourette syndrome.

Requires the Director to develop a system to collect data on Tourette syndrome, including epidemiological information regarding its incidence and prevalence in the United States, primary data, and data on the availability of medical and social services for individuals with Tourette syndrome and their families.

 Requires the Director to award grants and contracts to public or nonprofit private entities to pay costs of planning, establishing, improving, and providing basic operating support for between four and six centers of excellence in different regions of the United States to conduct basic and clinical research on Tourette syndrome.

Requires the Director to designate a portion of the amounts made available to carry out NIH programs and activities for a fiscal year to carry out programs and activities with respect to Tourette syndrome.
Topic: Health — R&D
Subject: Health
Date: 2013-05-06 00:00:00

Accelerating the End of Breast Cancer Act of 2013 - Establishes the Commission to Accelerate the End of Breast Cancer to help end breast cancer by January 1, 2020.

Directs the Commission to identify, recommend, and promote initiatives, partnerships, and research within the public and private sectors, basic and applied sciences, and epidemiology that can be turned into strategies to prevent breast cancer and breast cancer metastasis while giving priority to those that are: (1) not prioritized within the public sector, and (2) unlikely to be achieved by the private sector due to technical and financial uncertainty.

Requires the Commission to: (1) submit within six months to the President and to the relevant congressional committees a description of the Commission's strategic plan; (2) submit an annual report to the President, Congress, and the public; and (3) ensure that its activities are coordinated with, and do not duplicate the efforts of, programs and laboratories of other government agencies.

Directs the President to enter into an agreement with the Institute of Medicine to evaluate the Commission's progress.

Terminates the Commission on June 1, 2020.
Topic: Health — R&D
Subject: Health
Date: 2013-05-22 00:00:00

Amends the Public Health Service Act to authorize the Secretary of Health and Human Services (HHS) to: (1) establish a working group made up of representatives from various Institutes and Centers within the National Institutes of Health (NIH) to update and streamline NIH rehabilitation research priorities, and (2) enter into interagency agreements relating to the coordination of rehabilitation research conducted by agencies outside of HHS.

Requires the Secretary to report to Congress on the feasibility of implementing the changes proposed in the Blue Ribbon Panel Recommendations on Rehabilitation Research.
Topic: Health — R&D
Subject: Government operations and politics
Date: 2013-06-04 00:00:00

Directs the United States Postal Service (USPS) to issue and sell an Alzheimer's Disease Research Semipostal Stamp.

Requires proceeds from the sale of the stamp to be transferred to the National Institutes of Health.

Requires the stamp to be made available to the public for six years.
Topic: Health — R&D
Subject: Health
Date: 2013-06-27 00:00:00

Scleroderma Research and Awareness Act - Requires the Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases to expand, intensify, and coordinate the Institute's activities with respect to scleroderma, with particular emphasis on: (1) research focused on the etiology of scleroderma and the development of new treatment options, (2) clinical research to evaluate new treatment options, (3) basic research on the relationship between scleroderma and secondary conditions, (4) establishment of scleroderma patient registries, and (5) support for training of new clinicians and investigators with expertise in scleroderma.

Directs the Secretary of Health and Human Services (HHS), acting through the Director of the Centers for Disease Control and Prevention (CDC), to carry out an educational campaign to increase public awareness of scleroderma.
Topic: Health — R&D
Subject: Health
Date: 2013-06-27 00:00:00

Pediatric, Adolescent, and Young Adult Cancer Survivorship Research and Quality of Life Act of 2013 - Amends the Public Health Service Act to allow the Secretary of Health and Human Services (HHS) to make grants to eligible entities to establish pilot programs to develop, study, or evaluate model systems for monitoring and caring for childhood cancer survivors.

Authorizes the Secretary to convene a Workforce Development Collaborative on Medical and Psychosocial Care for Pediatric Cancer to establish a plan to meet specified objectives relating to medical and psychosocial care workforce development, including: (1) disseminating to health care educators information relevant to providing medical and psychosocial services to individuals with pediatric cancers, (2) adapting curricula for continuing education of the existing workforce, and (3) strengthening the emphasis on psychosocial health care in educational accreditation standards and professional licensing and certification.
Topic: Health — R&D
Subject: Health
Date: 2013-09-26 00:00:00

Next Generation Research Act - Amends the Public Health Service Act to establish the Next Generation of Research Initiative in the Office of the Director of the National Institutes of Health (NIH) for coordination of all NIH policies and programs aimed at promoting and providing opportunities for new researchers.

Requires the Director to: (1) promote existing policies and programs to improve opportunities for new researchers; (2) develop or modify policies, including to strengthen mentorship programs and enhance diversity efforts; and (3) request the National Academy of Sciences, as part of the required studies concerning biomedical and behavioral research personnel, to conduct a comprehensive study and report on policies affecting the next generation of researchers.
Topic: Health — R&D
Subject: Health
Date: 2014-03-12 00:00:00

American Cures Act - Establishes a Biomedical Research Fund to be administered by the Secretary of the Treasury to provide for an expanded and sustained national investment in biomedical research.

Requires amounts to be transferred from the Fund for each fiscal year to accounts related to the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), the Department of Defense (DOD) health program, and the medical and prosthetics research program of the Department of Veterans Affairs (VA) to ensure that funding for such programs and agencies does not fall below 105% of the level of funding provided for the preceding fiscal year and an additional amount to account for any increases in the Gross Domestic Product for the year involved.

Requires that amounts appropriated for each of such programs and agencies for a fiscal year be not be less than the amounts appropriated for FY2014. Authorizes and appropriates to the Fund such sums as necessary in each fiscal year to enable such transfers.

Amends the Balanced Budget and Emergency Deficit Control Act to exempt the Fund from any sequestration order issued under such Act.
Topic: Health — R&D
Subject: Health
Date: 2014-03-13 00:00:00

Regenerative Medicine Promotion Act of 2014 - Requires the Comptroller General to submit to Congress a report identifying all ongoing federal programs and activities regarding regenerative medicine.

Directs the Secretary of Health and Human Services (HHS) to establish a Regenerative Medicine Coordinating Council, which shall:

 prepare a national strategy to support research into regenerative medicine and enable the development of drugs, biological products, medical devices, and biomaterials for use in regenerative medicine; develop national goals for regenerative medicine research and product development; prepare a plan specifying priorities for research into regenerative medicine; identify sources of funding for research into regenerative medicine and areas where such funding is inadequate or duplicative; make recommendations regarding federal policies to support development and marketing of regenerative medicine products; develop consensus standards regarding scientific issues critical to regulator approval of regenerative medicine products; and determine the need for establishing centers of excellence or consortia to further advance regenerative medicine. Directs the Council to: (1) adopt procedures to ensure the receipt of public input; and (2) submit an annual report on its activities to Congress, the Director of the National Institutes of Health (NIH), and the Commissioner of Food and Drugs (FDA).
Topic: Health — R&D
Subject: Commerce
Date: 2014-03-24 00:00:00

Independent Innovator and Repurposing Act - Establishes procedures under which the term of an unexpired patent claiming a method of using a biological product shall be extended for five years from its original expiration date.

 Requires an application for such an extension to demonstrate that: (1) the patent was issued to an independent innovator, and (2) the owner of record is the independent innovator or a small business (with fewer than 500 employees and which is not affiliated with the holder of the marketing application approved under licensing requirements of the Public Health Service Act for the commercial marketing of such biological product) in which the independent innovator has an ownership interest.

Defines "independent innovator" as a person or entity that obtains a method of use patent for a biological product and is not, at the time of invention or patent filing, affiliated with the holder of an approved application for the commercial marketing of the product.
Topic: Health — R&D
Subject: Health
Date: 2014-07-24 00:00:00

Accelerating Biomedical Research Act - Amends the Balanced Budget and Emergency Deficit Control Act of 1985 to require certain adjustments to discretionary spending limits in FY2015-FY2021 to accommodate increases in appropriations to the National Institutes of Health (NIH) at the Department of Health and Human Services (HHS).